Skip to main content
Publications
Sherif B , Burke M, Besse B, Solomon B, Bazhenova L, Kim DW, Lin JJ, Wolf J, Popat S, Goto K, de Langen AJ, Springfeld C, Reynolds M , Odom D , Yuan Y, Lee A, Blum SI, Thamake S, Ades F, Drilon A. Health-related quality-of-life of patients treated with repotrectinib for neurotrophic tyrosine receptor kinase (NTRK)-positive advanced solid tumors: results From TRIDENT-1 . Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S484. doi: 10.1016/j.jval.2023.09.2619
Todenhofer T, Fizazi K, Shore ND, Tammela T, Kuss I, Le Barre M-A, Mohammed AF, Odom D , Bartsch J , Snapir A, Sarapohja T, Smith MR. Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (PTS) with nonmetastatic castrate-resistant prostate cancer (NMCRPC) . Poster presented at the 2020 German Cancer Congress; February 2020. [abstract] Oncol Res Treat. 2020 Feb; 43(Suppl 1):154-5. Previously presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
Schjesvold F, Goldschmidt H, Maisnar V, Spicka I, Abildgaard N, Rowlings P, Odom D , Gnanasakthy A , Suryanarayan K, Cain L, Romanus D, Rajkumar SV, Dimopoulos MA. Health-related quality of life (HRQOL) outcomes of oral ixazombi maintenance therapy post autologous stem cell transplant (ASCT) in newly diagnosed mulitple myeloma (NDMM) from TOURMALINE-MM3 . Poster presented at the 24th Congress of the European Hematology Association; June 2019. Amsterdam, The Netherlands. [abstract] Hemasphere. 2019 Jun; 3:266-7.
White MV, Silvia S, Hollis K , Wooddell M, Goss D , Odom D , Cooney D, Bartsch J , Hogue S. EPIPEN4SCHOOLS® survey combined analysis: prevalence and triggers of anaphylactic events . Poster presented at the 2016 AAAAI Annual Meeting; March 4, 2016. Los Angeles, CA. [abstract] J Allergy Clin Immunol. 2016; 137:AB52.
Matharu M, Pascual J, Nilsson Remahl L, Straube A, Johannes C , Odom D , Gutierrez L , Andrews E, Lum A. Interim analysis of the real-world utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine in an observational study in the European Union . Poster presented at the International Headache Conference; May 14, 2015. Valencia, Spain. [abstract] Cephalalgia. 2015; 35(6S):39.